beat strong keytruda vaccin
sale y/i our/con est mainli driven keytruda
vaccin portfolio proquad gardasil keytruda revenu y/i
q/q beat our/con estim strength across major
tumor proquad notic outperform y/i although
product benefit wholesal buy benefit wont repeat
op margin bp better forecast abl gener non-gaap
ep y/i also beat our/con est respect
given favor result rais sale ep guidanc
respect rais ep out-yr est remain rel unchang
though sale reflect acceler sale ramp
keytruda gardasil remain bullish modest po trim strictli
reflect conserv termin valu assumpt vs prior given
keytruda patent expiri result po prior maintain
buy rate base keytruda gardasil upsid margin expans undemand
takeaway call
takeaway us keytruda focus launch progress new tumor indic
nsclc market share new us patient start uptak
rcc progress well keytruda garner share patient risk group base
broad label ex-u keytruda seen rapid growth y/i
sale management comment intern market eu china japan signific
opportun bull case believ ex-u keytruda could repres total
peak sale suggest ex-u keytruda upsid china nrdl list lung
cancer still wait invit negoti favor result would
expand commerci opportun patient vaccin portfolio global
gardasil sale ytd strong demand pediatr yr old
although proquad revenu posit impact measl outbreak growth
trend expect sustain near long term ex stock benefit
continu focu bolt-on deal instead larg
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
rate buy offer attract valuat
good track record return cash
sharehold diversifi revenu base
substanti pipelin potenti keytruda
billion
billion
billion
billion
higher low- mid-singl digit rate
lower mid-singl digit rate
higher low-singl digit rate
higher mid-singl digit rate
price object po base blend averag risk-adjust
discount cash flow dcf price-to-earnings multipl appli ep dcf assum
wacc termin growth rate believ dcf assumpt
reason given minim contribut new keytruda indic
yet valid late-stag clinic studi erod revenu base
januvia/janumet zepati neg termin growth target price-to-earnings
multipl base regress analysi histor us major pharma
forward price-to-earnings multipl three-year forward compound-annual-growth-rate non-gaap
risk competitor report result look substanti better
shown keytruda chemotherapi higher-than-anticip price pressur
diabet franchis neg result late-stag clinic program
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
